Current openings at Initial Therapeutics

Initial Therapeutics is pursuing a bold and original mission: discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages.  Initial’s approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.

Initial Therapeutics was formed in 2020 and is currently operating in labs in South San Francisco, with a substantial (8- figure) Series A commitment.  Initial is founded by world-renowned scientists who bring relevant expertise and proprietary technology to enable them to address high-confidence, heretofore difficult-to-drug targets in cancer and neurodegeneration.  Screening of proprietary libraries is in progress.

Initial Therapeutics is founder-led and offers a dynamic start-up environment with a close-knit team of highly skilled, mission-driven professionals. We seek colleagues who are inspired to push the boundaries of small molecule discovery using novel approaches and who excel at identifying innovative solutions to challenging problems.

At Initial Therapeutics you’ll find a career where every day brings you adventures, challenges, and breakthroughs.  Join a dynamic, diverse, and growing team dedicated to developing transformative therapies that will revolutionize the future of cancer treatment and outcomes. Initial offers a competitive compensation and benefits package.